Bank of Montreal Can bought a new position in Arbutus Biopharma Corp. (NASDAQ:ABUS) during the second quarter, Holdings Channel reports. The firm bought 810,785 shares of the biopharmaceutical company’s stock, valued at approximately $2,822,000.
Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) traded up 0.35% during midday trading on Monday, hitting $2.88. 125,963 shares of the stock were exchanged. The firm’s 50 day moving average is $3.61 and its 200-day moving average is $4.00. Arbutus Biopharma Corp. has a 1-year low of $2.72 and a 1-year high of $6.40. The stock’s market capitalization is $157.81 million.
Arbutus Biopharma Corp. (NASDAQ:ABUS) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.36. Arbutus Biopharma Corp. had a negative return on equity of 8.87% and a negative net margin of 1,017.01%. On average, analysts predict that Arbutus Biopharma Corp. will post ($3.35) EPS for the current year.
ABUS has been the topic of several analyst reports. Leerink Swann reissued a “buy” rating on shares of Arbutus Biopharma Corp. in a research report on Wednesday, July 20th. William Blair initiated coverage on shares of Arbutus Biopharma Corp. in a research report on Friday, August 19th. They set a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research raised shares of Arbutus Biopharma Corp. from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Wednesday, October 5th. Chardan Capital raised shares of Arbutus Biopharma Corp. from a “sell” rating to a “neutral” rating and set a $3.00 price target on the stock in a research report on Friday. They noted that the move was a valuation call. Finally, Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of Arbutus Biopharma Corp. in a research report on Wednesday, July 20th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Arbutus Biopharma Corp. presently has an average rating of “Buy” and a consensus target price of $7.33.
About Arbutus Biopharma Corp.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Corp. (NASDAQ:ABUS).
Receive News & Ratings for Arbutus Biopharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.